Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332679 | 0.88 | L3MBTL1 (0.63) | MAPTALDH1A1POLB | |
| SCHEMBL1186577 | 0.79 | KMT2A (0.50) | SCN2AMAPTHTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10799631 | 0.77 | KMT2A (0.49) | SCN2AMAPTHTTMEN1KMT2A | |
| SCHEMBL2627226 | 0.77 | SCN2A (0.57) | SCN2AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL30782027 | 0.77 | SCN2A (0.57) | SCN2AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13298656 | 0.75 | KDM4E (0.55) | SCN2AMAPTHTTMEN1KMT2A | |
| SCHEMBL17678275 | 0.74 | HTT (0.55) | MAPTHTTMEN1KMT2ASIRT6 | |
| SCHEMBL27909482 | 0.74 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1ACHEHSD17B10 | |
| SCHEMBL22567 | 0.74 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1ACHEHSD17B10 | |
| SCHEMBL4449726 | 0.73 | NOTUM (0.55) | SCN2AMAPTHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-1394162-A1 | Intermediates of azole antifungal agents and processes for the preparation thereof | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1231210-A2 | Azole antifungal agents, processes for the preparation thereof, and intermediates | Eisai Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| CN-1087017-C | Azole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-07-03 | — | — | CN | disclosed |
| US-6362206-B1 | FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| US-6034248-A | FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| US-5792781-A | EFFECTIVE AGAINST DERMATOMYCOSIS/VISCEROMYCOSIS CAUSED BY FUNGI, I.E., CANDIDA ALBICANS | EISAI CO., LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5789429-A | FUNGICIDE | EISAI CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| CN-1175950-A | Azole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-03-11 | — | — | CN | disclosed |
| US-5648372-A | TRIAZOLES | EISAI CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0667346-A2 | Azole antifungal agents, process for the preparation there of and intermediates | Eisai Co., Ltd. (JP) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SCN2A 4565/4885MAPT 1391/4885HTT 1255/4885 |
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | SCN2A 4277/4885MAPT 2227/4885HTT 554/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | SCN2A 4565/4885MAPT 1391/4885HTT 1255/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | SCN2A 4277/4885MAPT 2227/4885HTT 554/4885 |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SCN2A 4565/4885MAPT 1391/4885HTT 1255/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | SCN2A 4195/4885MAPT 2428/4885HTT 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.